Health ❯ Healthcare ❯ Clinical Trials

Drug Development

Combination Therapy Eli Lilly Targeted Therapy Alzheimer's Treatments Phase III Trials Phase 3 Trials Phase 2 Trials Oral Medications Patient Outcomes Phase 1/2 Trials

Autolus Reports Q4 Loss, Reaffirms 2026 Sales Outlook for AUCATZYL, and Starts AUTO8 Trial

Management ties the 2026 outlook to higher patient volumes driving manufacturing leverage.

Upstream Bio Sets Phase 3 Start for Verekitug in Severe Asthma and Nasal Polyps

RTW Buys $116 Million of Cogent Biosciences as Kynam Trims $48 Million Stake

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

FDA Approves Vanda’s Bysanti for Bipolar I Mania and Schizophrenia

Priovant’s Brepocitinib Posts Strong Phase 2 Win in Cutaneous Sarcoidosis

Spanish Team Eradicates Pancreatic Tumors in Mice With Triple-Drug Regimen, PNAS Study Finds

Triple-Drug Strategy Wipes Out Pancreatic Tumors in Mice, Study Finds

Lilly Strikes Up to $1.12 Billion Pact With Seamless Therapeutics for Hearing‑Loss Gene Editing

Eupraxia Reports Early EoE Trial Data With Near‑Normal Tissue at Top Dose

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

FDA Clears First New Oral Gonorrhea Antibiotics in Over 30 Years

FDA Grants Fast Track to Palvella’s QTORIN Rapamycin for Angiokeratomas

Study Finds CBD–THC Combination Kills Ovarian Cancer Cells in Lab

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain